Patient-specific naturally gene-reverted induced pluripotent stem cells in recessive dystrophic epidermolysis bullosa
about
hiPSC-derived iMSCs: NextGen MSCs as an advanced therapeutically active cell resource for regenerative medicineProgress toward Treatment and Cure of Epidermolysis Bullosa: Summary of the DEBRA International Research Symposium EB2015Advances in understanding and treating dystrophic epidermolysis bullosaProgress and prospects of engineered sequence-specific DNA modulating technologies for the management of liver diseasesDystrophic epidermolysis bullosa: a reviewStem cell and tissue engineering in breast reconstructionModulating the stem cell niche for tissue regeneration.Placenta-based therapies for the treatment of epidermolysis bullosa"...Rewritten in the skin": clues to skin biology and aging from inherited disease.Use of induced pluripotent stem cells in dermatological research.Gene editing toward the use of autologous therapies in recessive dystrophic epidermolysis bullosa.Spontaneous ATM Gene Reversion in A-T iPSC to Produce an Isogenic Cell Line.From marrow to matrix: novel gene and cell therapies for epidermolysis bullosa.Novel and emerging therapies in the treatment of recessive dystrophic epidermolysis bullosa.Therapies for inherited skin fragility disorders.Review of the 94th Annual Meeting of the British Association of Dermatologists, Glasgow 2014.Revertant mosaicism in genodermatoses.The three-body problem of therapy with induced pluripotent stem cells.Ex Vivo COL7A1 Correction for Recessive Dystrophic Epidermolysis Bullosa Using CRISPR/Cas9 and Homology-Directed Repair
P2860
Q26751506-E423D989-F44E-4AC1-81CE-5490D7B1C497Q26775276-8A1FF544-2A1A-4C3F-99D8-B65908461392Q27006669-DE3310C6-09CF-4329-8FF0-6098E26FDBCDQ27011249-781196C3-0972-4FFF-AAC2-80F813A5519EQ28084871-D7FA0A73-44F4-4521-8519-53E3FD33DC35Q33973210-2F0EA0F5-056E-4728-BB53-A388B8B9D75DQ34432431-D28BC7B6-814D-44D4-818A-260998C4EA9DQ35582332-1AD6A45E-E0E5-4CD2-A9FE-FE7031032A8AQ35920445-650DFCD6-4427-43BA-9545-B1E017BF3ACBQ35924230-D5DDB0B8-56D3-4C2B-B0A2-1BB3A4AF9271Q36326838-27DAC6B4-87AC-47CB-AFD0-6567392FD503Q36379473-CAC0B5DB-F420-433A-979B-0A092D5DBDE4Q36756725-8FE18E69-E9C9-4D44-8503-463F2ADE3F8AQ37712686-3DA2EE09-D4E3-498F-8C05-9306F0049FB8Q38444460-7567E00E-F703-4F9D-AF4D-BB29589DC26EQ38473549-10BE9F4F-4179-4F32-8C7C-8C51EF52CAABQ39123627-3DC4E01F-D375-41E3-BCAB-52C1C4FAF13BQ42058337-6197B646-C4E0-4006-9B96-8488E1728382Q57159704-CB54DA6C-03B7-4077-9960-254B68198A78
P2860
Patient-specific naturally gene-reverted induced pluripotent stem cells in recessive dystrophic epidermolysis bullosa
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 06 December 2013
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Patient-specific naturally gen ...... strophic epidermolysis bullosa
@en
Patient-specific naturally gen ...... trophic epidermolysis bullosa.
@nl
type
label
Patient-specific naturally gen ...... strophic epidermolysis bullosa
@en
Patient-specific naturally gen ...... trophic epidermolysis bullosa.
@nl
prefLabel
Patient-specific naturally gen ...... strophic epidermolysis bullosa
@en
Patient-specific naturally gen ...... trophic epidermolysis bullosa.
@nl
P2093
P2860
P356
P1476
Patient-specific naturally gen ...... strophic epidermolysis bullosa
@en
P2093
Chris J Lees
Cindy Eide
Douglas R Keene
John A McGrath
John E Wagner
Mark J Osborn
Megan J Riddle
Troy C Lund
P2860
P2888
P304
P356
10.1038/JID.2013.523
P407
P577
2013-12-06T00:00:00Z